AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18670195
Drug: Formulation 14
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 14
Trial: 18670195
Drug: Formulation 17
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 17
Trial: 15154363
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid addition with standard therapy
Trial: 7516019
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg i.v. infusion)
Trial: 7516019
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg oral daily for 5 days)
Trial: 29554385
Drug: Intravitreous aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous aflibercept injection (IAI) with a fixed bimonthly regimen for the first 2 years, followed by routine clinical practice regimen in the third year.
Trial: 22999261
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg twice daily; PO)
Trial: 22999261
Drug: Metformin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (750 mg twice daily; PO)
Trial: 21371770
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg lipoic acid (LA)
Trial: 21371770
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg α-tocopherol
Trial: 21371770
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg α-tocopherol + 600 mg lipoic acid (LA)
Trial: 12057717
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) at a dose of 1.8 g/day orally for 5-6 weeks; 3 g/day for massively obese subjects
Trial: 7175716
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g probenecid
Trial: 7175716
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g probenecid
Trial: 29449764
Drug: Neuroplasticity explanation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroplasticity explanation with manual therapy
Trial: 29449764
Drug: Mechanical explanation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical explanation with manual therapy
Trial: 26374743
Drug: N-Acetyl Cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetyl Cysteine (NAC) 3 g/day (1.5 g twice daily)
Trial: 17631083
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of digoxin therapy
Trial: 14716705
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg b.d.)
Trial: 14716705
Drug: Milnacipran (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (100 mg per day for 7 days)
Trial: 12803656
Drug: Current treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatments for MG
Trial: 9845709
Drug: Standard triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone)
Trial: 7852209
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) therapy
Trial: 3188866
Drug: Active physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active physical therapy combined with 2 hours of passive knee motion twice daily from 2-12 days after total knee arthroplasty
Trial: 3188866
Drug: Active physical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active physical therapy only
Trial: 26715040
Drug: Augmented cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented cognitive behavioural therapy (augmented CBT)
Trial: 19192463
Drug: Continuation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation and maintenance antidepressant medication
Trial: 15215815
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/d for 1 week) plus Clopidogrel (75 mg/d for 3 weeks)
Trial: 15215815
Drug: Warfarin (international
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (international normalized ratio, 2 to 3 for 3 weeks)
Trial: 8398293
Drug: Clodronate (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (1.6 g daily)
Trial: 3598328
Drug: Intravenous alpha-2
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alpha-2 interferon (50 X 10(6) U/m2) on 5 consecutive days every 4 weeks
Trial: 3598328
Drug: Subcutaneous alpha-2
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous alpha-2 interferon (20 X 10(6) U/m2) three times per week
Trial: 3598328
Drug: Intravenous alpha-2
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alpha-2 interferon (20 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Trial: 3598328
Drug: Subcutaneous alpha-2
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous alpha-2 interferon (5 X 10(6) U/m2 per day) in combination with intravenous 5-Fluorouracil (250-500 mg/m2 per day on the first 5 days of each 4-week cycle)
Trial: 28606437
Drug: Price-aware group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Price-aware group (surgeons received implant prices)
Trial: 28606437
Drug: Price-naïve group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Price-naïve group (surgeons did not receive implant prices)
Trial: 23419552
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (iCBT) programme
Trial: 16359965
Drug: Luteinizing hormone
RxNorm normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone (LH)
Trial: 16359965
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of MIS with reproductive hormones and insulin
Trial: 9496522
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 mg subcutaneously 30 min before and 8 and 16 hours after ERCP
Trial: 31487271
Drug: Linked dual-class
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linked dual-class drug resistance mutations (DRMs) present before ART initiation
Trial: 31487271
Drug: Linked single-class
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linked single-class drug resistance mutations (DRMs) present before ART initiation
Trial: 31487271
Drug: Combination ART
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ART with 3 drugs (nevirapine/tenofovir/emtricitabine)
Trial: 28991344
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and systemic treatment (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and timolol maleate 0.5% gel)
Trial: 28991344
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment only (oral propranolol 1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks and simple eye ointment)
Trial: 27306492
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral chlorzoxazone
Trial: 22016348
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 17)
Trial: 19535243
Drug: CEF (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (adjuvant epirubicin-based chemotherapy)
Trial: 19535243
Drug: CMF (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (adjuvant methotrexate-based chemotherapy)
Trial: 19535243
Drug: TIMP-1 status
RxNorm normalized name: chlorcyclizine hydrochloride 2.5 MG/ML / codeine phosphate 1.8 MG/ML / pseudoephedrine hydrochloride 6 MG/ML [Statuss Green Reformulated Jan 2012]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMP-1 status (positive or negative) versus treatment (CMF or CEF) interaction
Trial: 15293606
Drug: One-stage LAUP
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage LAUP treatment
Trial: 15293606
Drug: Placebo (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (simulated snore surgery followed by an oral placebo)
Trial: 11887802
Drug: Bicarbonate/lactate-based solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/lactate-based solution (B/L)
Trial: 11887802
Drug: Lactate-based control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-based control solution (C)
Trial: 9512112
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg + Amoxicillin 1.5 g (LA group; 21 patients)
Trial: 9512112
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg + Amoxicillin 1.5 g + Rebamipide 300 mg (LAM group; 36 patients)
Trial: 7802317
Drug: Acelysin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acelysin infusion
Trial: 24423909
Drug: Nutritional liquid
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional liquid supplement designed for diabetes mellitus
Trial: 18715244
Drug: Intravaginal dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal dinoprostone (2 mg once every 6 hours)
Trial: 16907931
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg day‐1; n=13)
Trial: 16907931
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg day‐1; n=13)
Trial: 16907931
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (quinapril + atorvastatin)
Trial: 2088770
Drug: IdB 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdB 1016 (360 mg silybin equivalent)
Trial: 2088770
Drug: Silymarin (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (360 mg silybin equivalent)
Trial: 2088770
Drug: IdB 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdB 1016 (120 mg b.i.d. for 8 days)
Trial: 276348
Drug: Tumour cell
RxNorm normalized name: Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour cell vaccine
Trial: 28541810
Drug: Carbohydrate-, glutamine-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-, glutamine-, and antioxidant-enriched oral nutrition supplement (S)
Trial: 27295381
Drug: Topical bFGF
RxNorm normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bFGF application
Trial: 23537456
Drug: Pharmacotherapy follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy follow-up (PF) via clinical pharmacy intervention at monthly visits over a 3-month follow-up period
Trial: 23537456
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (Control Group)
Trial: 20613498
Drug: Routine stenting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine stenting with drug-eluting stents (DES) in both branches (group MV plus SB)
Trial: 19010201
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 10 ppm from the start of LT until 48 hours afterward
Trial: 19010201
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iNO treatment)
Trial: 14672246
Drug: Nutritionally-sourced TRP
RxNorm normalized name: Trp
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutritionally-sourced TRP (1.8 g daily)
Trial: 11013378
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (50-200 mg per day)
Trial: 8345068
Drug: Follicle-stimulating hormone
RxNorm normalized name: Follicle-stimulating hormone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicle-stimulating hormone (FSH) (Metrodin)
Trial: 20462632
Drug: Active art
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active art therapy
Trial: 18337480
Drug: High-dose CVVHDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CVVHDF (35 ml/kg per h)
Trial: 18337480
Drug: Standard-dose CVVHDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CVVHDF (20 ml/kg per h)
Trial: 15968293
Drug: Anti-CD25 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD25 monoclonal antibody (basiliximab)
Trial: 11211367
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy and behavioral treatment
Trial: 11211367
Drug: Titration-determined dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration-determined dose
Trial: 9723557
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous pump spray (Rhinocort Aqua) 32, 64, 128, or 256 microg once daily for 6 weeks
Trial: 9723557
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous pump spray (256 microg)
Trial: 9723557
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous pump spray (any active treatment group)
Trial: 9723557
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous pump spray
Trial: 7982869
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg per dose
Trial: 7982869
Drug: Methylphenidate 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.6 mg/kg per dose
Trial: 223601
Drug: calcium clofibrate
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium clofibrate and calcium carbonate (4C, 2 + 2 g/day for 6 months)
Trial: 223601
Drug: clofibrate (1C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clofibrate (1C, 2 g/day for 6 months)
Trial: 27836508
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus (L. rhamnosus) HN001 probiotic treatment for 4 weeks
Trial: 26163236
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (MMC)
Trial: 21890526
Drug: Topiramate (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (daily use, titrated to maximum 200 mg/day for 3 months)
Trial: 15047537
Drug: Quinine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine with primaquine at 15 mg/day
Trial: 15047537
Drug: Quinine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine with primaquine at 30 mg/day
Trial: 9564064
Drug: 0.5% intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% intraperitoneal subdiaphragmatic lidocaine 40 ml and 0.5% bupivacaine 5 ml infiltration of cannula insertion sites
Trial: 21372034
Drug: SR13668 (38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR13668 (38 mg oral dose)
Trial: 19727884
Drug: Seal oil
RxNorm normalized name: seal oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal oil capsules (340 mg EPA, 230 mg DPA, 450 mg DHA)
Trial: 19727884
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (210 mg EPA, 30 mg DPA, 810 mg DHA)
Trial: 19727884
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (containing sunola oil)
Trial: 17387133
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg of reconstituted HDL (CSL‐111)
Trial: 15114551
Drug: Pressure support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure support ventilation (PSV) with volume guarantee (VG) (Vt = 5 ml/kg) (n = 30)
Trial: 11605121
Drug: Ipratropiumbromide inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropiumbromide inhalation with RC-Cornet(R)
Trial: 11605121
Drug: Ipratropiumbromide inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropiumbromide inhalation with conventional inhalation (Pari-system)
Trial: 2688737
Drug: Azathioprine 50
RxNorm normalized name: azathioprine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 50 mg t.d.s.
Trial: 31741073
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of dexamethasone injected within 10 minutes of detected LOS in Group 2 (G2)
Trial: 25114060
Drug: Autologous adipose-derived
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose-derived stromal vascular fraction (SVF) injection
Trial: 23569370
Drug: UMEC 500
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 500 μg/VI 25 μg
Trial: 23569370
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg (administered on days 9-13)
Trial: 19922877
Drug: Timolol gel-forming
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol gel-forming solution 0.5%
Trial: 17124643
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract WS 5570 (900 mg/d or 1800 mg/d)
Trial: 17124643
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/d or 40 mg/d)
Trial: 9643220
Drug: Tretinoin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin (0.25 mg daily of 0.1% tretinoin cream)
Trial: 2426902
Drug: Various established
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various established topical and systemic treatment regimes
Trial: 16279889
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg combined with clarithromycin 500 mg and amoxicillin 1 g for 1 week
Trial: 16279889
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg combined with clarithromycin 500 mg and amoxicillin 1 g for 1 week
Trial: 12411798
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group (50 mg/kg as a bolus, then 8 mg x kg(‐1) x h(‐1))
Trial: 12411798
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.9% sodium chloride solution)
Trial: 12411798
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group (propofol infusion rate maintained at 80 microg x kg(‐1) x min(‐1))
Trial: 12411798
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (propofol infusion rate maintained at 160 microg x kg(‐1) x min(‐1))
Trial: 10470755
Drug: Traditional tidal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional tidal volume ventilation (10-12 mL/kg ideal body weight)
Trial: 10470755
Drug: Reduced tidal
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced tidal volume ventilation (5-8 mL/kg ideal body weight)
Trial: 1283851
Drug: Vinorelbine (single-agent)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (single-agent)